Top Markets
Coin of the day
DelMar Pharmaceuticals, Inc. DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc.

DMPWW
Rangering i aksjer #42376
Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc.... Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.
Aksjekurs
$0.005
Sist synkronisert: 2024-06-20
Markedsverdi
$1.74K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel DelMar Pharmaceuticals, Inc. (DMPWW)

Kategori

P/S-forhold for DelMar Pharmaceuticals, Inc. (DMPWW)
P/S-forhold per 2026 TTM: 0
Ifølge DelMar Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for DelMar Pharmaceuticals, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR